Watson David O. (CIK 0001657719)

Latest company ownership

APLS - Apellis Pharmaceuticals, Inc.
Role: General Counsel
Shares held
60,136
Last filed at
Nov 18, 2025
Confidence Score
23.4
2025Q4
Confidence Score History
2018Q3 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Dec 16, 2025 Dec 18, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.96% ✓ $122.5K
Nov 17, 2025 Nov 18, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.88% ✓ $100.3K
Oct 16, 2025 Oct 17, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.80% ✓ $126.1K
Sep 16, 2025 Sep 18, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.72% ✓ $121.7K
Sep 10, 2025 Sep 12, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 20.0 -20,000 -9.81% ✗ $523.4K
Aug 18, 2025 Aug 19, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.39% ✓ $139K
Jul 16, 2025 Jul 18, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.34% ✓ $97.8K
Jun 16, 2025 Jun 18, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 41.3 -5,000 -2.28% ✓ $93.9K
Mar 4, 2025 Mar 6, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 22.5 -5,569 -2.48% ✗ $139.8K
Jan 29, 2025 Jan 30, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 51.3 -695 -0.31% ✗ $20.5K
Jan 22, 2025 Jan 23, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 42.5 -3,323 -1.45% ✗ $101.1K
Jan 17, 2025 Jan 21, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 95.0 +40,561 21.59% ✗ $65.9K
Jan 13, 2025 Jan 14, 2025 Apellis Pharmaceuticals, Inc. General Counsel Sell 42.5 -4,965 -2.57% ✗ $142.5K
Dec 11, 2024 Dec 13, 2024 Apellis Pharmaceuticals, Inc. General Counsel Sell 22.5 -5,000 -2.53% ✗ $171.2K
Feb 12, 2024 Feb 13, 2024 Apellis Pharmaceuticals, Inc. General Counsel Sell 47.5 -781 -0.40% ✗ $52.9K
Jan 29, 2024 Jan 31, 2024 Apellis Pharmaceuticals, Inc. General Counsel Sell 47.5 -906 -0.46% ✗ $58.1K
Jan 22, 2024 Jan 23, 2024 Apellis Pharmaceuticals, Inc. General Counsel Sell 40.0 -4,184 -2.09% ✗ $271.9K
Jan 16, 2024 Jan 17, 2024 Apellis Pharmaceuticals, Inc. General Counsel Sell 97.5 +19,508 10.81% ✗ $283.3K
Dec 19, 2023 Dec 20, 2023 Apellis Pharmaceuticals, Inc. General Counsel Sell 22.5 -3,905 -2.12% ✗ $223.5K
Jul 3, 2023 Jul 6, 2023 Apellis Pharmaceuticals, Inc. General Counsel Sell 35.0 -8,510 -4.60% ✓ $765.7K
Feb 21, 2023 Feb 22, 2023 Apellis Pharmaceuticals, Inc. General Counsel Sell 86.3 +9,061 5.15% ✗ $48.3K
Feb 10, 2023 Feb 14, 2023 Apellis Pharmaceuticals, Inc. General Counsel Sell 43.8 -532 -0.30% ✗ $27.2K
Jan 27, 2023 Jan 30, 2023 Apellis Pharmaceuticals, Inc. General Counsel Sell 43.8 -551 -0.31% ✗ $29.1K
Jan 20, 2023 Jan 24, 2023 Apellis Pharmaceuticals, Inc. General Counsel Sell 22.5 -2,034 -1.14% ✗ $105.9K
Jun 22, 2022 Jun 23, 2022 Apellis Pharmaceuticals, Inc. General Counsel Sell 20.0 -10,000 -7.38% ✗ $445.1K
Apr 21, 2022 Apr 27, 2022 Apellis Pharmaceuticals, Inc. General Counsel Sell 35.0 -6,875 -4.83% ✓ $250K
Feb 10, 2022 Feb 14, 2022 Apellis Pharmaceuticals, Inc. General Counsel Sell 51.3 -491 -0.34% ✗ $23.1K
Jan 28, 2022 Feb 1, 2022 Apellis Pharmaceuticals, Inc. General Counsel Sell 51.3 -650 -0.45% ✗ $25.1K
Dec 27, 2021 Dec 28, 2021 Apellis Pharmaceuticals, Inc. General Counsel Sell 22.5 -1,200 -1.01% ✗ $58.2K
Dec 22, 2021 Dec 23, 2021 Apellis Pharmaceuticals, Inc. General Counsel Sell 20.0 -10,571 -3.09% ✗ $505.4K
Feb 10, 2021 Feb 11, 2021 Apellis Pharmaceuticals, Inc. General Counsel Sell 43.8 -468 -0.44% ✗ $22.3K
Dec 11, 2020 Dec 15, 2020 Apellis Pharmaceuticals, Inc. General Counsel Sell 20.0 -18,333 -5.32% ✗ $933.9K
Feb 10, 2020 Feb 12, 2020 Apellis Pharmaceuticals, Inc. General Counsel Sell 87.5 +1,375 3.12% ✓ $222.5K
Jan 27, 2020 Jan 28, 2020 Apellis Pharmaceuticals, Inc. General Counsel Sell 28.8 -3,000 -9.36% ✓ $121.4K
Sep 14, 2018 Sep 17, 2018 Apellis Pharmaceuticals, Inc. General Counsel Sell 20.0 -15,776 -36.84% ✗ $296.3K